Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05334732 · ClinicalTrials.gov registry record · NA

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

A NA study of Breast Cancer, sponsored by Virginia Commonwealth University.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
3
Study locations

NCT05334732 is a NA study of Breast Cancer that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 250 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05334732, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.

Conditions Studied

Interventions

  • BEHAVIORAL SIS TALK Back Intervention

Study Locations (3)

District of Columbia

  • Medstar Georgetown University Hospital - Washington D.C.
  • MedStar Washington Hospital Center - Washington D.C.

Virginia

  • Massey Cancer Center - Richmond

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2021-03-01
Est. Completion 2026-02-28
Phase NA

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT05334732

The ClinicalTrials.gov registry entry for NCT05334732 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SIS TALK Back Intervention is the first listed.

NCT05334732 reports 3 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Virginia.

Frequently Asked Questions

What is clinical trial NCT05334732 about?

NCT05334732 is a clinical study titled "Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)". The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.

What is the current status of trial NCT05334732?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2021-03-01. Estimated completion is 2026-02-28.

What conditions does trial NCT05334732 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05334732?

The interventions under investigation include: SIS TALK Back Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05334732?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05334732 being conducted?

This trial has 3 study locations across District of Columbia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.